Mitchell E. Levinson - Mar 22, 2022 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Chief Strategy Officer
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol
PLSE
Transactions as of
Mar 22, 2022
Transactions value $
$0
Form type
4
Date filed
3/24/2023, 04:30 PM
Previous filing
Aug 20, 2021
Next filing
Jun 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Award +35K 35K Mar 22, 2023 Common Stock 35K $2.92 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on March 22, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to performance-based vesting criteria. 8,750 shares will vest in equal annual installments over the following four years on or about December 31, starting in 2023, subject to achievement of the vesting criteria and the reporting person's continued service through each vesting date.
F2 Not Applicable